Lipella Pharmaceuticals Files 8-K for Material Agreement
Ticker: LIPO · Form: 8-K · Filed: Feb 24, 2025 · CIK: 1347242
| Field | Detail |
|---|---|
| Company | Lipella Pharmaceuticals Inc. (LIPO) |
| Form Type | 8-K |
| Filed Date | Feb 24, 2025 |
| Risk Level | medium |
| Sentiment | neutral |
Sentiment: neutral
Topics: material-agreement, filing, corporate-event
TL;DR
Lipella Pharma (LIPAF) filed an 8-K on 2/24 for a material agreement. Watch for details.
AI Summary
On February 24, 2025, Lipella Pharmaceuticals Inc. filed an 8-K report detailing a material definitive agreement and financial statements. The filing was made on February 24, 2025, with the earliest event reported on February 23, 2025. The company is incorporated in Delaware and its principal executive office is located in Pittsburgh, PA.
Why It Matters
This 8-K filing indicates a significant event for Lipella Pharmaceuticals, potentially related to a new contract or partnership, which could impact its future operations and financial performance.
Risk Assessment
Risk Level: medium — 8-K filings often signal significant corporate events, but without specific details on the material agreement, the immediate impact and associated risks are unclear.
Key Players & Entities
- Lipella Pharmaceuticals Inc. (company) — Registrant
- February 24, 2025 (date) — Date of Report
- February 23, 2025 (date) — Earliest Event Reported
- Delaware (jurisdiction) — State of Incorporation
- Pittsburgh, PA (location) — Principal Executive Office
FAQ
What is the nature of the material definitive agreement filed by Lipella Pharmaceuticals?
The filing indicates the entry into a material definitive agreement, but the specific details of this agreement are not provided in the provided text.
When was the earliest event reported in this 8-K filing?
The earliest event reported in this 8-K filing was on February 23, 2025.
What is Lipella Pharmaceuticals Inc.'s state of incorporation?
Lipella Pharmaceuticals Inc. is incorporated in Delaware.
Where are Lipella Pharmaceuticals Inc.'s principal executive offices located?
Lipella Pharmaceuticals Inc.'s principal executive offices are located at 7800 Susquehanna St., Suite 505, Pittsburgh, PA 15208.
What is the SEC file number for Lipella Pharmaceuticals Inc.?
The SEC file number for Lipella Pharmaceuticals Inc. is 001-41575.
Filing Details
This Form 8-K (Form 8-K) was filed with the SEC on February 24, 2025 regarding LIPELLA PHARMACEUTICALS INC. (LIPO).